| NCT01074931 | HIV-1 Infections | Drug: Lopinavir/ritonavir (Kaletra) | Abbott | | 2008-04-01 | 2011-07-07 |
| NCT02503462 | AIDS-related Dementia Complex | Drug: Darunavir|Drug: ritonavir|Drug: cobicistat | University Hospital, Basel, Switzerland | Phase 4 | 2015-07-01 | 2017-02-01 |
| NCT00985543 | Acquired Immunodeficiency Syndrome | Drug: lopinavir/ritonavir | Kirby Institute | Phase 1 | 2009-10-01 | 2011-03-02 |
| NCT01810887 | Healthy | Drug: Darunavir|Drug: Ritonavir | Janssen Pharmaceutical K.K. | Phase 4 | 2008-05-01 | 2013-04-09 |
| NCT00885495 | HIV Infections | Drug: darunavir, ritonavir, rosuvastatin|Drug: rosuvastatin, darunavir, ritonavir | University of Cincinnati | Phase 1|Phase 2 | 2009-01-01 | 2009-04-21 |
| NCT01047995 | HIV Infections | Drug: Raltegravir plus Darunavir/ritonavir|Drug: Raltegravir plus Darunavir/ritonavir | St Stephens Aids Trust | Phase 1 | 2009-06-01 | 2010-01-12 |
| NCT00621166 | HIV Infections | Drug: generic lopinavir/ritonavir | The HIV Netherlands Australia Thailand Research Collaboration | Phase 2 | 2008-06-01 | 2012-04-03 |
| NCT00477126 | Healthy | Drug: GPO ritonavir versus Norvir | The HIV Netherlands Australia Thailand Research Collaboration|The Government Pharmaceutical Organization | Phase 1 | 2007-01-01 | 2012-04-03 |
| NCT01172535 | HIV | Drug: Lopinavir/ritonavir | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2|Phase 3 | 2010-11-01 | 2015-11-16 |
| NCT02034838 | HIV Infection | Drug: atazanavir 300mg boosted with ritonavir 50 mg | Ottawa Hospital Research Institute|Bristol-Myers Squibb | Phase 1 | 2014-01-01 | 2015-09-21 |
| NCT01237444 | HIV Infection | Drug: lopinavir/ritonavir plus one nucleoside|Drug: lopinavir /ritonavir plus two nucleosides | Pedro Cahn|Abbott|The Huesped Foundation | Phase 3 | 2010-12-01 | 2012-06-08 |
| NCT01700790 | AIDS|Tuberculosis | Drug: Lopinavir/ritonavir and ritonavir | University of Miami|Oswaldo Cruz Foundation | Phase 4 | 2016-01-01 | 2016-12-06 |
| NCT01581853 | HIV | Drug: Lopinavir/ritonavir 800 mg / 200mg | Daniel Podzamczer|Hospital Universitari de Bellvitge | Phase 4 | 2012-05-01 | 2016-10-05 |
| NCT02348177 | Acquired Immunodeficiency Syndrome|Tuberculosis | Drug: lopinavir with ritonavir in 1:1 ratio|Drug: Lopinavir/ritonavir 4:1 | Drugs for Neglected Diseases|University of Cape Town|Medecins Sans Frontieres, Netherlands|French Development Agency|UBS Optimus Foundation | Phase 4 | 2013-01-01 | 2015-01-22 |
| NCT01002898 | HIV | Drug: lopinavir/ritonavir soft gel capsule | Bamrasnaradura Infectious Diseases Institute | Phase 3 | 2007-04-01 | 2011-11-10 |
| NCT01009437 | Breast Cancer | Drug: ritonavir|Procedure: therapeutic conventional surgery | Masonic Cancer Center, University of Minnesota|Susan G. Komen Breast Cancer Foundation | Phase 1|Phase 2 | 2010-05-01 | 2016-01-21 |
| NCT01258439 | HIV|Cardiovascular Disease | Drug: raltegravir plus truvada|Drug: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada) | St Vincent's Hospital, Sydney|Merck Sharp & Dohme Corp. | Phase 4 | 2010-11-01 | 2015-01-08 |
| NCT01695954 | Hyperlipidemia|HIV | Drug: Pitavastatin|Drug: Darunavir|Drug: Ritonavir|Drug: Efavirenz | New York University School of Medicine|Bellevue/NYU AIDS Clinical Trials Unit|Kowa Pharmaceuticals America, Inc.|University at Buffalo | Phase 1 | 2012-05-01 | 2012-09-27 |
| NCT00855413 | Acute HIV Infection|HIV Infections | Drug: Darunavir/Ritonavir and Etravirine | University of North Carolina, Chapel Hill|Janssen Pharmaceuticals | Phase 4 | 2009-03-01 | 2014-10-14 |
| NCT02527707 | Chronic Delta Hepatitis | Drug: lonafarnib|Drug: Ritonavir | Eiger BioPharmaceuticals|Hannover Medical School | Phase 2 | 2015-09-01 | 2016-09-14 |
